<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> MK-801 in reducing ischaemic brain damage have been examined in anaesthetised cats, with drug treatment being initiated 2 h after the induction of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> was produced by permanent occlusion of one middle cerebral artery, and the animals were killed 6 h later </plain></SENT>
<SENT sid="2" pm="."><plain>The amount of early irreversible ischaemic damage was assessed at 16 predetermined stereotactic planes </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with MK-801 (5 mg/kg, i.v.) 2 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> reduced significantly the volume of ischaemic damage (from 1,625 +/- 384 mm3 of the cerebral hemisphere in vehicle-treated cats to 792 +/- 385 mm3 in MK-801-treated cats) </plain></SENT>
<SENT sid="4" pm="."><plain>The demonstration of reduced ischaemic brain damage with MK-801, when the agent is administered after the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, extends the therapeutic potential of such agents in the treatment of focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in humans </plain></SENT>
</text></document>